Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

First International Summit on Interventional Pharmacoeconomics

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Deborah Collyar: What's In It for Patients?

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Cost of Care

The ASCO Post Staff

Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

Allen S. Lichter, MD, of the Value in Cancer Care Consortium, interviews Clifford A. Hudis, MD, Chief Executive Officer of ASCO, on the question of whether cancer drug prices in the United States are the problem, or just the symptom, of a larger systemic issue.

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Jun

Today In Oncology

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Related Videos

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Deborah Collyar: What's In It for Patients?

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Annual Galleri Screening Reduced Stage IV Cancer Diagnoses but Missed Primary Endpoint in First Randomized MCED Trial

GLP-1 RAs Associated With Lower Breast Cancer Incidence

American Cancer Society Updates Colorectal Cancer Screening Guideline

Long-Term Follow-Up of Three First-Line Regimens in Mantle Cell Lymphoma

Does Tissue TMB Outperform Blood-Based Testing for Predicting Immunotherapy Response